Cargando…

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)

SUMMARY: Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in the benefits of drug therapy. Improving medication adherence is urgently needed but remains laborious, given the numerous and multidimensional reasons for non-adhe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiligsmann, M., Cornelissen, D., Vrijens, B., Abrahamsen, B., Al-Daghri, N., Biver, E., Brandi, M.L., Bruyère, O., Burlet, N., Cooper, C., Cortet, B., Dennison, E., Diez-Perez, A., Gasparik, A., Grosso, A., Hadji, P., Halbout, P., Kanis, J.A., Kaufman, J.M., Laslop, A., Maggi, S., Rizzoli, R., Thomas, T., Tuzun, S., Vlaskovska, M., Reginster, J.Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811382/
https://www.ncbi.nlm.nih.gov/pubmed/31388696
http://dx.doi.org/10.1007/s00198-019-05104-5
_version_ 1783462467153690624
author Hiligsmann, M.
Cornelissen, D.
Vrijens, B.
Abrahamsen, B.
Al-Daghri, N.
Biver, E.
Brandi, M.L.
Bruyère, O.
Burlet, N.
Cooper, C.
Cortet, B.
Dennison, E.
Diez-Perez, A.
Gasparik, A.
Grosso, A.
Hadji, P.
Halbout, P.
Kanis, J.A.
Kaufman, J.M.
Laslop, A.
Maggi, S.
Rizzoli, R.
Thomas, T.
Tuzun, S.
Vlaskovska, M.
Reginster, J.Y.
author_facet Hiligsmann, M.
Cornelissen, D.
Vrijens, B.
Abrahamsen, B.
Al-Daghri, N.
Biver, E.
Brandi, M.L.
Bruyère, O.
Burlet, N.
Cooper, C.
Cortet, B.
Dennison, E.
Diez-Perez, A.
Gasparik, A.
Grosso, A.
Hadji, P.
Halbout, P.
Kanis, J.A.
Kaufman, J.M.
Laslop, A.
Maggi, S.
Rizzoli, R.
Thomas, T.
Tuzun, S.
Vlaskovska, M.
Reginster, J.Y.
author_sort Hiligsmann, M.
collection PubMed
description SUMMARY: Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in the benefits of drug therapy. Improving medication adherence is urgently needed but remains laborious, given the numerous and multidimensional reasons for non-adherence, suggesting the need for measurement-guided, multifactorial and individualized solutions. INTRODUCTION: Poor adherence to medications is a major challenge in the treatment of osteoporosis. This paper aimed to provide an overview of the consequences, determinants and potential solutions to poor adherence and persistence to osteoporosis medication. METHODS: A working group was organized by the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO) to review consequences, determinants and potential solutions to adherence and to make recommendations for practice and further research. A systematic literature review and a face-to-face experts meeting were undertaken. RESULTS: Medication non-adherence is associated with increased risk of fractures, leading to a substantial decrease in the clinical and economic benefits of drug therapy. Reasons for non-adherence are numerous and multidimensional for each patient, depending on the interplay of multiple factors, suggesting the need for multifactorial and individualized solutions. Few interventions have been shown to improve adherence or persistence to osteoporosis treatment. Promising actions include patient education with counselling, adherence monitoring with feedback and dose simplification including flexible dosing regimen. Recommendations for practice and further research were also provided. To adequately manage adherence, it is important to (1) understand the problem (initiation, implementation and/or persistence), (2) to measure adherence and (3) to identify the reason of non-adherence and fix it. CONCLUSION: These recommendations are intended for clinicians to manage adherence of their patients and to researchers and policy makers to design, facilitate and appropriately use adherence interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-019-05104-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6811382
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-68113822019-11-05 Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) Hiligsmann, M. Cornelissen, D. Vrijens, B. Abrahamsen, B. Al-Daghri, N. Biver, E. Brandi, M.L. Bruyère, O. Burlet, N. Cooper, C. Cortet, B. Dennison, E. Diez-Perez, A. Gasparik, A. Grosso, A. Hadji, P. Halbout, P. Kanis, J.A. Kaufman, J.M. Laslop, A. Maggi, S. Rizzoli, R. Thomas, T. Tuzun, S. Vlaskovska, M. Reginster, J.Y. Osteoporos Int Consensus Statement SUMMARY: Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in the benefits of drug therapy. Improving medication adherence is urgently needed but remains laborious, given the numerous and multidimensional reasons for non-adherence, suggesting the need for measurement-guided, multifactorial and individualized solutions. INTRODUCTION: Poor adherence to medications is a major challenge in the treatment of osteoporosis. This paper aimed to provide an overview of the consequences, determinants and potential solutions to poor adherence and persistence to osteoporosis medication. METHODS: A working group was organized by the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO) to review consequences, determinants and potential solutions to adherence and to make recommendations for practice and further research. A systematic literature review and a face-to-face experts meeting were undertaken. RESULTS: Medication non-adherence is associated with increased risk of fractures, leading to a substantial decrease in the clinical and economic benefits of drug therapy. Reasons for non-adherence are numerous and multidimensional for each patient, depending on the interplay of multiple factors, suggesting the need for multifactorial and individualized solutions. Few interventions have been shown to improve adherence or persistence to osteoporosis treatment. Promising actions include patient education with counselling, adherence monitoring with feedback and dose simplification including flexible dosing regimen. Recommendations for practice and further research were also provided. To adequately manage adherence, it is important to (1) understand the problem (initiation, implementation and/or persistence), (2) to measure adherence and (3) to identify the reason of non-adherence and fix it. CONCLUSION: These recommendations are intended for clinicians to manage adherence of their patients and to researchers and policy makers to design, facilitate and appropriately use adherence interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-019-05104-5) contains supplementary material, which is available to authorized users. Springer London 2019-08-07 2019 /pmc/articles/PMC6811382/ /pubmed/31388696 http://dx.doi.org/10.1007/s00198-019-05104-5 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Consensus Statement
Hiligsmann, M.
Cornelissen, D.
Vrijens, B.
Abrahamsen, B.
Al-Daghri, N.
Biver, E.
Brandi, M.L.
Bruyère, O.
Burlet, N.
Cooper, C.
Cortet, B.
Dennison, E.
Diez-Perez, A.
Gasparik, A.
Grosso, A.
Hadji, P.
Halbout, P.
Kanis, J.A.
Kaufman, J.M.
Laslop, A.
Maggi, S.
Rizzoli, R.
Thomas, T.
Tuzun, S.
Vlaskovska, M.
Reginster, J.Y.
Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
title Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
title_full Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
title_fullStr Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
title_full_unstemmed Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
title_short Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
title_sort determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the european society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (esceo) and the international osteoporosis foundation (iof)
topic Consensus Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811382/
https://www.ncbi.nlm.nih.gov/pubmed/31388696
http://dx.doi.org/10.1007/s00198-019-05104-5
work_keys_str_mv AT hiligsmannm determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT cornelissend determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT vrijensb determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT abrahamsenb determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT aldaghrin determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT bivere determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT brandiml determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT bruyereo determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT burletn determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT cooperc determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT cortetb determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT dennisone determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT diezpereza determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT gasparika determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT grossoa determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT hadjip determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT halboutp determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT kanisja determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT kaufmanjm determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT laslopa determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT maggis determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT rizzolir determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT thomast determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT tuzuns determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT vlaskovskam determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost
AT reginsterjy determinantsconsequencesandpotentialsolutionstopooradherencetoantiosteoporosistreatmentresultsofanexpertgroupmeetingorganizedbytheeuropeansocietyforclinicalandeconomicaspectsofosteoporosisosteoarthritisandmusculoskeletaldiseasesesceoandtheinternationalost